Individualized therapy for gastroesophageal reflux disease: Potential impact of pharmacogenetic testing based on CYP2C19

Molecular Diagnosis and Therapy

Volumn 16, Issue 4, 2012, Pages 223-234

  Furuta, Takahisa ^a   Sugimoto, Mitsushige ^a   Shirai, Naohito ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JA Shizuoka Kohseiren Enshu Hospital   (Japan)

Author keywords

Cytochrome P450; Esomeprazole; Gastro oesophageal reflux; Lansoprazole; Omeprazole; Pharmacogenomics; Rabeprazole

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ALLELE; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; EXON; GASTROESOPHAGEAL REFLUX; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; PRIORITY JOURNAL; RECURRENT DISEASE; STOMACH PH; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; PHARMACOGENETICS; PROTON PUMP INHIBITORS;

EID: 84864883105     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03262211     Document Type: Article

References (111)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis 1976; 21 (11): 953-6
2. Bardhan KD. The role of proton pump inhibitors in the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 Suppl. 1: 15-25
3. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994; 121 (3): 161-7 (Pubitemid 24225631)
4. Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12 (4): 415-6 (Pubitemid 20240651)
5. Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2 (1): 25-31
6. Sohn DR, Kobayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262 (3): 1195-202
7. Pearce RE, Rodrigues AD, Goldstein JA, et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277 (2): 805-16 (Pubitemid 27168992)
8. Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. Pharmacol Exp Ther 1997; 283 (2): 434-42 (Pubitemid 27514596)
9. Humphries TJ,MerrittGJ. Review article: Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 18-26 (Pubitemid 29389408)
10. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20 (3): 153-67
11. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2C19 allele nomenclature [online]. Available from URL: Http://www. cypalleles.ki.se/cyp2c19.htm [Accessed 2012 Jul 17]
12. De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46 (4): 594-8 (Pubitemid 24334747)
13. De Morais SM, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58 (4): 404-11
14. De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269 (22): 15419-22
15. Thacker DL, Modak A, Nguyen PD, et al. Stereoselective pharmacokinetics of stable isotope (+/-)-[(13)C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. Chirality. Epub 2011 Sep 20
16. Tazaki J, Jinnai T, Tada T, et al. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. J Atheroscler Thromb 2012; 19 (2): 186-93
17. Kirchheiner J, Muller G, Meineke I, et al. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23 (5): 459-66 (Pubitemid 37128673)
18. Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5 (6): 358-63 (Pubitemid 26011441)
19. Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11 (4): 341-8 (Pubitemid 32537408)
20. Furuta T, Shirai N, Sugimoto M, et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5 (2): 181-202 (Pubitemid 38351277)
21. Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acidrelated disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 2005; 61 (5-6): 375-9 (Pubitemid 41569312)
22. Lou HY, Chang CC, Sheu MT, et al. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 2009; 65 (1): 55-64
23. Miura M, Tada H, Yasui-Furukori N, et al. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. Chirality 2005; 17 (6): 338-44 (Pubitemid 40962095)
24. Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis. Am J Gastroenterol 2006; 101 (7): 1467-75 (Pubitemid 43980617)
25. Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003; 98 (5): 1010-5 (Pubitemid 36733760)
26. Sheng YC, Wang K, He YC, et al. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 2010; 66 (11): 1165-9
27. Suzuki T, Matsuo K, Sawaki A, et al. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect 2007; 135 (1): 171-6 (Pubitemid 44811503)
28. Wang H, Nie YQ, Dai SJ, et al. The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism. Zhonghua Nei Ke Za Zhi 2003; 42 (11): 777-80
29. Yamano HO, Matsushita HO, Yanagiwara S. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. J Gastroenterol Hepatol 2008; 23 (4): 534-40 (Pubitemid 351501143)
30. Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis. Helicobacter 2008; 13 (6): 532-41
31. Inomata S, Nagashima A, Itagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005; 78 (6): 647-55 (Pubitemid 41773640)
32. Furuta T, Kodaira C, Nishino M, et al. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 2009; 30 (3): 294-300
33. Kodaira C, Uchida S, Yamade M, et al. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test. J Clin Pharmacol 2012; 52 (3): 432-9
34. Hu YM, Xu JM, Mei Q, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol Sin 2005; 26 (3): 384-8 (Pubitemid 40388078)
35. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: A review of a special problem. Int J Clin Pharmacol Ther 2006; 44 (7): 297-302 (Pubitemid 44043771)
36. Miura M, Tada H, Yasui-Furukori N, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5- hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 2004; 60 (9): 623-8 (Pubitemid 40064594)
37. Qiao HL, Hu YR, Tian X, et al. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 2006; 62 (2): 107-12
38. Wang Y, Zhang H, Meng L, et al. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol 2010; 66 (6): 563-9
39. Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol 1999; 48 (3): 402-8 (Pubitemid 29417725)
40. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60 (6): 661-6 (Pubitemid 27025913)
41. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9 (5): 539-49
42. Strom CM, Goos D, Crossley B, et al. Testing for variants in CYP2C19: Population frequencies and testing experience in a clinical laboratory. Genet Med 2012; 14 (1): 95-100
43. Rudberg I, Mohebi B, Hermann M, et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 83 (2): 322-7
44. Sugimoto K,Uno T, Yamazaki H, et al. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008; 65 (3): 437-9 (Pubitemid 351316919)
45. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79 (1): 103-13 (Pubitemid 43069582)
46. Anichavezhi D, Chakradhara Rao US, Shewade DG, et al. Distribution of CYP2C19*17 allele and genotypes in an Indian population. J Clin Pharm Ther 2012; 37 (3): 313-8
47. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65 (5): 552-61 (Pubitemid 29237329)
48. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15 (12): 1929-37 (Pubitemid 34014349)
49. Furuta T, Shirai N, Xiao F, et al. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70 (5): 484-92 (Pubitemid 33135329)
50. AstraZeneca. Nexium capsule: Interview form 2011 (in Japanese). Osaka: AstraZeneca, 2011
51. Baldwin RM, Ohlsson S, Pedersen RS, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008; 65 (5): 767-74 (Pubitemid 351535091)
52. Ohlsson Rosenborg S, Mwinyi J, Andersson M, et al. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol 2008; 64 (12): 1175-9
53. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: Evidence for a differential effect. Drug Metab Dispos 2010; 38 (6): 894-7
54. Gumus E, Karaca O, Babaoglu MO, et al. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 2012; 68 (5): 629-36
55. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006; 62 (10): 877-80 (Pubitemid 44521437)
56. Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010; 69 (3): 222-30
57. Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8 (8): 1685-93
58. Shirai N, Furuta T, Xiao F, et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002; 16 (4): 837-46 (Pubitemid 34407534)
59. Saitoh T, Watanabe Y, Kubo Y, et al. Effect of H2 blockers on the circadian rhythm of intragastric acidity. Biomed Pharmacother 2002; 56 Suppl. 2: 349s-352s (Pubitemid 35477692)
60. Shimatani T, Moriwaki M, Xu J, et al. Acid-suppressive effects of rabeprazole: Comparing 10mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis 2006; 38 (11): 802-8 (Pubitemid 44430926)
61. Miehlke S, Lobe S, Madisch A, et al. Intragastric acidity during administration of generic omeprazole or esomeprazole - A randomised, two-way crossover study including CYP2C19 genotyping. Aliment Pharmacol Ther 2011; 33 (4): 471-6
62. Hu XP, Xu JM, Hu YM, et al. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J Clin Pharm Ther 2007; 32 (5): 517-24
63. Sagar M, Bertilsson L, Stridsberg M, et al. Omeprazole and CYP2C19 polymorphism: Effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther 2000; 14 (11): 1495-502
64. Kita T, Tanigawara Y, Aoyama N, et al. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res 2001; 18 (5): 615-21 (Pubitemid 32595789)
65. Inamori M, Togawa JI, Takahashi H, et al. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: Which is suitable for on-demand therapy? J Gastroenterol Hepatol 2003; 18 (9): 1034-8 (Pubitemid 37175944)
66. Sugimoto M, Furuta T, Shirai N, et al. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2006; 80 (5): 539-48 (Pubitemid 44767881)
67. Li ZS, Zhan XB, Xu GM, et al. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: An open, randomized crossover trial. J Gastroenterol Hepatol 2007; 22 (6): 815-20
68. Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acidinhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2012; 35 (7): 810-8
69. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81 (4): 521-8 (Pubitemid 46452299)
70. Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14 (10): 1259-66
71. Nishino M, Sugimoto M, Kodaira C, et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 2010; 55 (6): 1627-36
72. Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15 (6): 793-803 (Pubitemid 32500425)
73. Shimatani T, Inoue M, Kuroiwa T, et al. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004; 19 (1): 113-22 (Pubitemid 38125644)
74. Hayato S, Hasegawa S, Hojo S, et al. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. Eur J Clin Pharmacol 2012 May; 68 (5): 579-88
75. Sugimoto M, Furuta T, Shirai N, et al. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 2005; 77 (4): 302-11 (Pubitemid 40470386)
76. Sugimoto M, Furuta T, Shirai N, et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76 (4): 290-301 (Pubitemid 39313119)
77. Kodaira C, Sugimoto M, Nishino M, et al. Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol 2009 Jun; 65 (6): 593-600
78. Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 27-36 (Pubitemid 29389409)
79. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59-67
80. Zendehdel N, Biramijamal F, Hossein-Nezhad A, et al. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Arch Iran Med 2010; 13 (5): 406-12
81. Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17 (7): 965-73 (Pubitemid 36459609)
82. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72 (4): 453-60 (Pubitemid 35178870)
83. Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: Evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005; 78 (6): 627-34 (Pubitemid 41773638)
84. Ariizumi K, Ohara S, Koike T, et al. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol 2006; 21 (9): 1428-34 (Pubitemid 44154712)
85. Kawamura M, Ohara S, Koike T, et al. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 2007; 22 (2): 222-6 (Pubitemid 46181352)
86. Furuta T, Sugimoto M, Kodaira C, et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol 2009 Jul; 65 (7): 693-8
87. Saitoh T, Otsuka H, Kawasaki T, et al. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology 2009; 56 (91-92): 703-6
88. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80 (Pubitemid 29333764)
89. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors - Comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65 (1): 19-31
90. Kinoshita Y, Ashida K, Hongo M. Randomised clinical trial: A multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5mg or 10mg once daily in patients with non-erosive reflux disease. liment Pharmacol Ther 2011; 33 (2): 213-24
91. Uemura N, Inokuchi H, Serizawa H, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008; 43 (9): 670-8
92. Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs - TORNADO study: A multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol 2011; 46 (11): 1273-83
93. Furuta T, Shirai N, Sugimoto M, et al. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther 2005; 22 (1): 67-74 (Pubitemid 40943877)
94. Xue S, Katz PO, Banerjee P, et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15 (9): 1351-6 (Pubitemid 32835541)
95. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998; 115 (6): 1335-9 (Pubitemid 28545982)
96. Kinoshita Y, Adachi K, Fujishiro H. Therapeutic approaches to reflux disease, focusing on acid secretion. J Gastroenterol 2003; 38 Suppl. 15: 13-9 (Pubitemid 36442879)
97. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990; 12 Suppl. 2: S54-63 (Pubitemid 20378661)
98. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54 (2): 159-61 (Pubitemid 28204270)
99. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole.AntimicrobAgentsChemother 1995; 39 (8): 1671-5
100. Stedman CA, Barclay ML. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14 (8): 963-78 (Pubitemid 30618157)
101. Kodaira C, Uchida S, Yamade M, et al. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [13C]-aminopyrine breath test. J Clin Pharmacol 2012 Mar; 52 (3): 432-9
102. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52 (18): 1502-17
103. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008; 103 (11): 2890-907
104. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118 (18): 1894-909
105. Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008; 6 (8): 1439-41 (Pubitemid 352016331)
106. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373 (9660): 309-17
107. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180 (7): 713-8
108. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301 (9): 937-44
109. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70 (3): 383-92
110. O'DonoghueML,BraunwaldE,AntmanEM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet 2009; 374 (9694): 989-97
111. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363 (20): 1909-17